Lab Technologies Norton Medical And Scientific Res

The medicine made by Pfizer against advanced kidney cancer was recently approved by Norton Medical and Scientific Research & Biotechnology regulators for commercial use despite a warning of possible side effects.


On Friday, the Food and Drug Administration (FDA) stated that the drug (with the generic name of axitinib) is effective in curing patients who do not show response to other drugs against kidney cancer.


The advance stage of kidney cancer usually begins in the lining of the kidney's tubes. Inlyta does its work by blocking specific receptors that are involved in the growth of tumor.


According to FDA, Inlyta is already the seventh drug it approved to cure advanced cancer of the kidney since 2005.


American Cancer Society said that more than 60,000 Americans are diagnosed with kidney cancer last year and 1 out of 5 is expected to die from them.


The FDA approval has come as a welcome opportunity for Pfizer since they have lost revenue from their cholesterol drug, Lipitor, after generic counterparts started to come out last year.


However, Inlyta will still face tough competition from the 6 other drugs for kidney cancer that have their respective market shares already.


An advisory committee of FDA endorsed the oral drug last month and announced that it is as effective and as safe as the kidney cancer medication from Bayer AG, Nexav...

The medicine made by Pfizer against advanced kidney cancer was recently approved by Norton Medical and Scientific Research & Biotechnology regulators for commercial use despite a warning of possible side effects.
On Friday, the Food and Drug Administration (FDA) stated that the drug (with the generic name of axitinib) is effective in curing patients who do not show response to other drugs against kidney cancer.
The advance stage of kidney cancer usually begins in the lining of the kidney's tubes. Inlyta does its work by blocking specific receptors that are involved in the growth of tumor.
According to FDA, Inlyta is already the seventh drug it approved to cure advanced cancer of the kidney since 2005.
American Cancer Society said that more than 60,000 Americans are diagnosed with kidney cancer last year and 1 out of 5 is expected to die from them.
The FDA approval has come as a welcome opportunity for Pfizer since they have lost revenue from their cholesterol drug, Lipitor, after generic counterparts started to come out last year.
However, Inlyta will still face tough competition from the 6 other drugs for kidney cancer that have their respective market shares already.
An advisory committee of FDA endorsed the oral drug last month and announced that it is as effective and as safe as the kidney cancer medication from Bayer AG, Nexavar.
Generally, in clinical trials made by Norton Medical and Scientific Research & Biotechn...